
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune Inc. has a positive outlook due to its innovative product candidate, pemvidutide, which is a dual GLP-1/glucagon receptor agonist targeting obesity and metabolic diseases including metabolic dysfunction-associated steatohepatitis (MASH). The recent validation from Novo's acquisition of Akero Therapeutics highlights increasing interest in the MASH market and positions pemvidutide as a strategically relevant solution due to its leading tolerability profile and effective dual-action mechanism, which may simplify treatment regimens compared to combination therapies. Furthermore, alignment between preclinical data and clinical signals supports confidence in pemvidutide's potential to deliver significant clinical benefits, thereby enhancing Altimmune's standing in a rapidly evolving therapeutic landscape.
Bears say
Altimmune Inc faces several substantial risks that contribute to a negative outlook on its stock, primarily stemming from clinical development challenges associated with its investigational product candidate, pemvidutide. The company is also subjected to heightened competitor and commercialization risks, alongside potential reimbursement and pricing challenges that could hinder market entry and acceptance. Furthermore, external factors such as capital market volatility, possible dilution of shares, and disruptions from geopolitical events and health crises like COVID-19 could adversely affect the company's clinical trials and financial stability moving forward.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares